Get startedLog in
    Picture of Paradigm Biopharmaceuticals logo

    PAR — Paradigm Biopharmaceuticals News Story

    0.000.00%
    au flag iconLast trade - 00:00
    HealthcareSpeculativeSmall Cap
    All News

    Australia Stock Exchange release from PARADIGM BIOPHAR : FIRST MPS-VI PATIENT DOSED UNDER PHASE 2 TRIAL IN BRAZIL

    Picture of Paradigm Biopharmaceuticals logoParadigm Biopharmaceuticals
    30/09/2021 01:00
    Australia Stock Exchange release from PARADIGM BIOPHAR  PAR.AX : FIRST MPS-VI PATIENT DOSED UNDER PHASE 2 TRIAL IN BRAZIL

    Recent news on Paradigm Biopharmaceuticals

    See all news